Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 9/20 | 0.55 |
| ▸ | F10 | P00742 | 9/20 | 0.55 |
| ▸ | F7 | P08709 | 9/20 | 0.55 |
| ▸ | F3 | P13726 | 9/20 | 0.55 |
| ▸ | PLG | P00747 | 5/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7665736 | 0.86 | F3 (0.51) | F2F10F7F3PLG | |
| SCHEMBL7652022 | 0.77 | F3 (0.48) | F2F10F7F3PLG | |
| SCHEMBL8353247 | 0.77 | KDM4E (0.43) | F2F10F7F3PLG | |
| SCHEMBL6787476 | 0.73 | F3 (0.44) | F2F10F7F3PLG | |
| SCHEMBL13715871 | 0.73 | KMT2A (0.47) | F2F10F7F3PLG | |
| SCHEMBL24225548 | 0.72 | HPGD (0.71) | TP53HPGDNPSR1ALDH1A1NPC1 | |
| SCHEMBL7663122 | 0.72 | F3 (0.50) | F2F10F7F3PLG | |
| SCHEMBL7662258 | 0.71 | F10 (0.58) | F2F10F7F3PLG | |
| SCHEMBL7659215 | 0.71 | F7 (1.00) | F2F10F7F3PLG | |
| SCHEMBL7658328 | 0.71 | F7 (0.86) | F2F10F7F3PLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6936719-B2 | Biaryl compounds as serine protease inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2005-08-30 | — | — | US | disclosed |
| US-20040162281-A1 | Biaryl compounds as serine protease inhibitors | BIOCRYST PHARMACEUTICALS, INC. | 2004-08-19 | — | — | US | disclosed |
| US-6699994-B1 | ANTICOAGULANTS; INHIBITORS OF THROMBIN, BLOOD COAGULATION FACTORS VIIA, XA, FVIIA, TISSUE FACTOR, AND TRYPSIN | BIOCRYST PHARMACEUTICALS, INC. | 2004-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162281-A1 | Biaryl compounds as serine protease inhibitors | TFPI, SPINT2, TFPI2 | F2 4/4885F10 30/4885F7 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.